Adults with pre-existing medical situations who’ve already obtained the Moderna or Pfizer double vaccinations and a third shot will be capable to get a booster shot, federal well being officers say.
“People who are moderately and severely immunocompromised may receive a total of four COVID-19 vaccine doses,” the Centers for Disease Control stated in its pointers up to date Tuesday.
The CDC licensed a third dose for immunocompromised individuals 18 and older in August. The fourth shot needs to be obtained at the least six months after the third, the CDC stated. The CDC doesn’t contemplate the third pictures now being authorized for Moderna and Pfizer vaccines as boosters.
Some medical situations and coverings could make it troublesome for immunocompromised individuals to construct and retain immunity, ensuing within the want for a fourth shot, the CDC says.
Also within the information:
► More than 75% of Maine’s eligible inhabitants is now absolutely vaccinated and about 70% of your entire inhabitants is absolutely vaccinated, in line with state information launched Wednesday. About 58% of your entire U.S. inhabitants is absolutely vaccinated.
► Oregon Gov. Kate Brown obtained a vaccine booster shot and inspired different eligible Oregonians to debate booster pictures with docs. Brown had the Johnson & Johnson single-shot earlier this 12 months, and Tuesday she obtained a Moderna shot.
► Massachusetts training officers have extended the mask requirement in all Ok-12 public faculties by at the least Jan. 15. School officers can carry the native mandate if they will reveal that at the least 80% of all college students and workers are vaccinated.
► Australian Health Minister Greg Hunt introduced that double-vaccinated Australians will be allowed to travel abroad and/or return dwelling beginning Monday. Many households have been cut up aside by the tight border closure that went into impact in March 2020.
►A Brazilian Senate committee advisable on Tuesday that President Jair Bolsonaro face a collection of felony indictments for actions and omissions associated to the world’s second-highest COVID-19 dying toll.
📈 Today’s numbers: The U.S. has recorded 45.6 million confirmed COVID-19 circumstances and greater than 738,000 deaths, in accordance to Johns Hopkins University data. Global totals: More than 244.6 million circumstances and 4.9 million deaths. More than 190 million Americans – 57% of the inhabitants – are absolutely vaccinated, in line with the CDC.
📘 What we’re studying: Own an iPhone? You can now maintain a digital model of your COVID-19 vaccine card right in your phone’s Apple Wallet.
Keep refreshing this web page for the most recent information. Want extra? Sign up for USA TODAY’s Coronavirus Watch newsletter to obtain updates on to your inbox and be a part of our Facebook group.
- COVID’s prompt millionaires. What did they do with the money?
- Louisiana eases masks mandate as an infection charge plummets
- Merck to share COVID-19 system with nations in want
- FDA panel recommends Pfizer vaccine for youths as younger as 5
- US coronavirus numbers proceed to enhance
- Maker of COVAXIN vaccine seems to start out US trials
Pete Vegas had simply returned from trip along with his 5 grandkids when he obtained a unusual textual content telling him he’d received $1 million. He thought it was a hoax. Vegas, a Colorado resident, was a winner of the state’s COVID-19 vaccine lottery, designed to incentivize individuals to get the shot. He’s planning to make use of the cash to combat local weather change.
“My immediate reaction was guilt,” stated Vegas, 65. “Both my wife and I said, wow, we can’t keep this money. We have to do something good with it.”
Several states funded vaccines lotteries, and at the least 24 individuals nationwide claimed a $1 million prize. Here’s a have a look at what another vaccine millionaires did with the loot. Read more here.
Louisiana Gov. John Bel Edwards lifted his statewide COVID mask mandate aside from faculties, which should heed advisable quarantine insurance policies earlier than shedding face coverings. Edwards cited a dramatic fall within the state’s an infection charge and hospitalizations that prompted his choice. He additionally famous the potential for youngsters to be eligible for vaccines inside weeks, whereas bemoaning Louisiana’s lagging vaccination charge as forty fifth within the nation: “We have to do better.” Individual metropolis and parish authorities leaders, similar to New Orleans Mayor Latoya Cantrell, and enterprise house owners may nonetheless mandate masks at their discretion.
“We have made tremendous progress and I have no doubt that reinstating the mask mandate was a key to this,” Edwards stated.
– Greg Hilburn, Lafayette Daily Advertiser
U.S.-based pharmaceutical large Merck announced a licensing agreement to offer “affordable” international entry to its coronavirus drug molnupiravir. The oral, antiviral medication is for remedy of mild-to-moderate COVID-19 in adults who’re in danger for progressing to extreme COVID-19 and/or hospitalization. The settlement with the Medicines Patent Pool (MPP), which works to make medical remedy and applied sciences globally accessible, will present 105 low and center earnings international locations with entry to the drug.
“Merck’s mission to save lots of and enhance lives is a really international dedication,” said Frank Clyburn, president of Merck’s Human Health division. “This settlement with MPP is one other necessary component in our multi-faceted technique to speed up broad, reasonably priced entry to molnupiravir.”
After a discussion where it was pointed out that more than 40% of American children ages 5 to 11 had contracted COVID-19 by the end of June, a panel of Food and Drug Administration advisers voted 17-0 Tuesday to authorize the Pfizer-BioNTech coronavirus vaccine for kids that age.
The resounding support is a major step forward for making school-age children eligible for inoculation – likely by next week – but there are still three crucial hurdles to clear: The FDA will have to sign off, an independent CDC advisory panel will review the data, and then the CDC director would have to give her clearance.
Pfizer-BioNTech reported 10 micrograms of their vaccine, a third of the dose administered to adults, is 90.7% effective at preventing symptomatic COVID, a growing concern for children.
One study presented by the CDC found that 42% of children ages 5 to 11 in the U.S. had been infected with COVID-19 as of the end of June. Support for the children’s vaccine comes as a USA TODAY analysis of data from Johns Hopkins University shows that new coronavirus infections are down 56.8% nationwide since the delta variant surge peaked in the first week of September.
The United States has passed one important milestone in its recovery from a delta variant-driven surge of coronavirus and is close to another. Johns Hopkins University data shows the United States reported fewer than 500,000 cases a week through Monday, a number that fell to 476,873 in the seven-day period ending Tuesday. The country hadn’t been below 500,000 since July 29, and went on to report some 1.15 million cases in the week ending Sept. 4.
With cases falling for nearly two months, deaths have also been falling and appear likely to soon fall below 10,000 per week. The country reported 10,346 deaths in the seven-day period ending Tuesday, the lowest the count has been since Sept. 6, a holiday, after which every week has reported at least 10,000 deaths. Deaths in the delta-driven wave peaked at 14,648 on Sept. 22, or about 2,100 per day.
– Mike Stucka
Another COVID-19 vaccine maker is hoping to enter the U.S. market, this time with a traditional type of shot that has already been delivered more than 100 million times in India.
Ocugen Inc., a publicly traded company based in Malvern, Pennsylvania, announced Wednesday morning that it has submitted an application to the Food and Drug Administration to begin a trial in the United States of its vaccine, COVAXIN.
The vaccine uses a whole-killed virus, meaning it delivers into the body an inactivated form of the coronavirus. This stimulates a broader immune response than vaccines currently available in the United States, and is more similar to the immune protection provided by a COVID-19 infection, according to Dr. Bruce Forrest, Ocugen’s acting chief medical officer.
Although COVAXIN has been used in India since early this year, the FDA prefers to base its approvals on data collected in the U.S. The vaccine also includes a new adjuvant – meant to boost the effect on the immune system – that was developed by the National Institutes of Health.
The company expects to finish its trial in the middle of next year and Forrest said the vaccine could be used as a two-dose initial regimen or as a booster shot.
COVAXIN prevented 93% of circumstances of extreme illness and was 78% protecting towards signs of illness and 64% efficient towards asymptomatic illness, in company-funded research in India.
Contributing: The Associated Press